IL6 and myocardial infarction: On the other hand, ziltivekimab, a monoclonal antibody directed against IL-6, downstream of IL-1, has shown to reduce inflammatory markers among patients with chronic kidney disease with a rather favourable safety profile.5 The ongoing phase IIIa ARTEMIS trial will determine whether ziltivekimab can effectively reduce the risk of MACE in patients with MI.